October 29, 2026 | Health Care | Europe | Active
On 21-Oct-26, Private equity firm EQT agreed to acquire molecular testing company Qiagen in a €9.6bn equity transaction. Our Deal Insight focuses on the risk that Qiagen’s operating performance and the merger agreement’s market-related provisions could complicate completion. We also examine shareholder acceptance, the German takeover process and the prospects for a competing proposal, alongside the regulatory clearances and timetable needed to complete the acquisition. Using takeover precedents, contractual analysis and valuation work, we assess the principal execution risks and the potential implications for the deal spread and downside scenarios. Published 29-Oct-26. Available to subscribers and qualified institutional investors upon request.
Contents
Please contact us to request access to this report.